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GATGATAATGTATTGCTACCAACAGATCCAATTGGAGGTAAAACAGGAATTAACTA 
TACTAATATATTTAATACTTATGGTCCTTTAACTGCATTAAATAATGTACCACCAGTT 
TATCCAAATGGTCAAATTTGGGATAAAGAATTTGATACTGACTTAAAACCAAGACTT 
494 
CATGT AAATGCACCA TTTGTTTGTCAAAA T AATTGCCCTGGTCAA TTA TTTGT AAAA 
GTTGCGCCTAATTTAACAAATGAATATGATCCTGATGCATCTGCTAATATGTCAAGA 
ATTGTAACTTACTCAGATTTTTGGTGGAAAGGTAAATTAGTATTTAAAGCTAAACTA 
AGAGCCTCTCATACTTGGAATCCAATTCAACAAATGAGTATTAATGTAGATAACCAA 
572 
TTTAACTATGTACCAAGTAATATTGGAGGTATGAAAATTGTCTATGAAAAATCTCAA 
CTAGCACCTAGAAAATTATATTAACATACTTACTATGTTTTTATGTTTATTACATAT 
Figure 1 
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426 431 
GATGATAATGTATTG~CCAACAGATCCAATTGGAGGTAAAACAGGAA1iAACTA 
TACTAATATATTTAATACTTATGGTCCTTTAACTGCATTAAATAATGTACCACCAGTT 
TATCCAAATGGTCAAATTTGGGATAAAGAATTTGATACTGACTTAAAACCAAGACTT 
494 
CATGTAAATGCACCATTTGTTTGTCAAAATAATIQ!;;CCTGGTCAATTATTTGTAAAA 
GTTGCGCCTAAITTAACAAATGAATATGATCCTGATGCATCTGCTAATATGTCAAGA 
ATTGTAACTTACTCAGATTTTTGGTGGAAAGGTAAATTAGTATTTAAAGCTAAACTA 
AGAGCCTCTCAT ACTTGGAA TCCAA TTCAACAAATGAGT A TT AA TGT AGAT AACCAA 
572 
TTTAACTATGTACCAAGTAATATTGGAGGTATGAAAATT~TATGAAAAATCTCAA 
CTAGCACCTAGAAAATTATATTAACATACTTACTATGTTTTTATGTTTATTACATAT 
Figure 2 
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GAAGATAATGTATTGCTACCAACAGATCCAATTGGAGGTAAAACAGGAATTAACTA 
TACTAATATATTTAATACTTATGGTCCTTTAACTGCATTAAATAATGTACCACCAGTT 
TATCCAAATGGTCAAATTTGGGATAAAGAATTTGATACTGACTTAAAACCAAGACTT 
494 
CATGTAAATGCACCATrTGTTTGTCAAAATAATTGTCCTGGTCAATTATTTGTAAAA 
GTTGCGCCTAATTTAACAAATGAATATGATCCTGATGCATCTGCTAATATGTCAAGA 
ATTGTAACTTACTCAGATTTTTGGTGGAAAGGTAAATTAGTATTTAAAGCTAAACTA 
AGAGCCTCTCATACTTGGAATCCAATTCAACAAATGAGTATTAATGTAGATAACCAA 
572 
TTTAACTATGTACCAAGTAATATTGGAGGTATGAAAATTGTA 
Figure 3 
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426 440 
GAAGATAATGTATTGCTACCAACAGATCCAATTGGAGGTAAA!i,CaGGAATTAACTA 
TACTAATATATTTAATACTfATGGTCCTTTAACTGCATTAAATAATGTACCACCAGTT 
TATCCAAATGGTCAAATTTGGGATAAAGAATTTGATACTGACTTAAAACCAAGACTT 
494 
CATGTAAATGCACCATTTGTTTGTCAAAATAATTGTCCTGGTCAATTATTTGTAAAA 
GTTGCGCCTAATTTAACAAATGAATATGATCCTGATGCATCTGCTAATATGTCAAGA 
ATTGTAACTTACTCAGATTTTTGGTGGAAAGGTAAATTAGTATTTAAAGCTAAACTA 
AGAGCCTCTCATACTTGGAATCCAATTCAACAAATGAGTATTAATGTAGATAACCAA 
572 
TTTAACTATGTACCAAGTAATATTGGAGGTATGAAAA11GTA 
Figure 4 
U.S. Patent Dec. 17, 2013 Sheet 5 of 9 US 8,609,404 B2 
426 430 440 
GAAGATAATGTAIIACTACCAACAGATCCAATTGGAGGTAAA~GGAATTAACTA 
TACTAATATATTTAATACTTATGGTCCTTTAACTGCATTAAATAATGTACCACCAGTT 
TATCCAAATGGTCAAATTTGGGATAAAGAATTTGATACTGACTTAAAACCAAGACTT 
494 
CA TOT AAA TGCACCA TTTGTTTGTCAAAAT AA TTGTCCTGGTCAA TT A TTTGT AA.AA 
GTTGCGCCTAATTTAACAAATGAATATGATCCTGATGCATCTGCTAATATGTCAAGA 
ATTGTAACTTACTCAGATTTTTGGTGGAAAGGTAAATTAGTATTTAAAGCTAAACTA 
AGAGCCTCTCATACTTGGAATCCAATTCAACAAATGAGTATTAATGTAGATAACCAA 
572 
TTTAACT ATGT ACCAAGT AA TA TTGGAGGT A TGAAAA TT.QT A 
Figure 5 
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426 
GACGATAATGTATTGCTACCAACAGATCCAATTGGAGGTAAAACAGGAATTAACTA 
TACTAATATATTTAATACITATGGTCCTTTAACTGCATTAAATAATGTACCACCAGTT 
TATCCAAATGGTCAAAITTGGGATAAAGAAITTGATACTGACTTAAAACCAAGACTT 
484 494 
CATGTGAATGCACCATTTGTTTGTCAAAATAATI!i,CCCTGGTCAATTATTTGTAAAA 
GTTGCGCCTAATTTAACAAATGAATATGATCCTGATGCATCTGCTAATATGTCAAGA 
A ITGT AACTTACTCAGA TTTTTGGTGGAAAGGT AAA TT AGT A TIT AAAGCT AAACT A 
546 
AGAGCCTCTCATACTTGGAACCCAATTCAACAAATGAGTATTAATGTAGATAACCAA 
572 
TTTAACT A TGT ACCAAGTAAT A TTGGAGGTATGAAAA TTGTC 
Figure 9 
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VACCINES CONTAINING CANINE 
PARVOVIRUS GENETIC VARIANTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation of U.S. patent applica-
tion Ser. No. 12/211,174 filed Sep. 16, 2008, now U.S. Pat. 
No. 8,227,583 which claims benefit ofU.S. provisional patent 
application 61/027,618, filed Feb. 11, 2008, and is a continu-
ation-in-part of U.S. patent application Ser. No. 12/138,085, 
filed Jun. 12, 2008, now U.S. Pat. No. 8,258,274 which also 
claims benefit of U.S. provisional patent application 61/027, 
618, filed Feb. 11, 2008 and U.S. provisional patent applica-
tion 60/943,947, filed Jun. 14, 2007, the complete contents of 
each of which are hereby incorporated by reference. 
SEQUENCE LISTING 
This application includes as the Sequence Listing the com-
plete contents of the accompanying text file "Sequence.txt", 
created Aug. 28, 2008, containing 4406 bytes, hereby incor-
porated by reference. 
DESCRIPTION 
Background of the Invention 
1. Field of the Invention 
The invention generally relates to improved canine par-
vovirus (CPV) vaccine formulations and diagnostic tests. In 
particular, the invention provides improved CPV vaccine for-
mulations and diagnostic tests comprising newly emerging 
dominant CPV variants currently circulating in canine popu-
lations. 
2. Background of the Invention 
Canine parvovirus (CPV) is primarily an enteric pathogen 
that infects dogs, especially young dogs. Parvovirus infection 
is characterized by acute diarrhea, fever and leukopenia in 
dogs and puppies more than 4 to 5 weeks old, and myocardial 
disease in younger puppies. The mortality rate from the dis-
ease in unvaccinated dogs is very high. While vaccines 
against CPV are available, because CPV is a single-stranded 
DNA virus and has an extreme ability to mutate, the virus 
shows a remarkable ability to vary antigenically and thereby 
elude the immune protection afforded by vaccines. Thus, 
constant monitoring of the antigenic type and genotype of the 
causative agent is necessary. 
2 
United States. For a review of CPV discovery and evolution, 
see Parrish and Kawaoka, 2005. 
CPV-2b differs from CPV-2a at only two amino acid posi-
tions: Asn-426 in 2a ( encoded by AAT) is Asp in 2b ( encoded 
5 by GAT), and Ile-555 in 2a is Val in 2b. The Ile-555 to Val 
change is actually a reversion to the original type 2 sequence. 
The CPV-2a and 2b antigenic types appeared to be relatively 
stable for a number of years. However, in 2000 a variant "2c" 
was described in which position 426 is Glu encoded by GAA 
10 (position 555 remains Val). The 2c variant has been reported 
in Italy (Buonavoglia et al., 2001 ), Vietnam (Nakamura et al., 
2001) and other countries, including Spain (Nakamura et al., 
2004; Decaro et al., 2006), but until now there have been no 
confirmed reports of the 2c variant in the United States, and 
15 CPV vaccines have not been updated to include such variants. 
This is of special importance because, unlike previously 
described variants that infect primarily puppies, CPV2c has 
the ability to infect adult dogs. Further, the sequence of a 2b 
variant with codon variations at positions 494 and 572 was 
20 submitted to GenBank (gi: 54646340) in 2003 and reported 
by Shackelton et al. in 2005 (Proceedings National Academy 
Sciences 102:379-384), but no alterations in CPV vaccine or 
diagnostic compositions were proposed based on such 
sequences. This may be in part due to the nature of the 
25 mutations, which are "silent" with respect to the encoded 
amino acids, i.e. the translated amino acid sequence of2b and 
the 2b variant with codon variations at positions 494 and 572 
are the same. However, recent studies concerning codon bias 
(Enserink, 2008. Science 320: 1709; Coleman 2008, Science 
30 320; 1784-87) show that codon bias may be a very important 
evolutionary tool oforganisms. Enserink states that" ... many 
organisms, including viruses, have a bias toward certain 
codons in their genes. This may be because those codons are 
easier to translate at ribosomes ... thus speeding up protein 
35 production ... ". Therefore, to successfully combat diseases 
for which viruses are the etiological agent, it is advisable to 
continuously monitor emerging variants and include preva-
lent variants in new, updated vaccine preparations, even if the 
changes that are detected do not result in a change in a trans-
40 lated amino acid sequence. 
Several problems arise when vaccines are not updated. 
Firstly, even vaccinated dogs may be susceptible to infection 
by CPV variants that are not included in the vaccine. Sec-
ondly, when vaccinated dogs become ill, their owners fre-
45 quently claim that the viral strains in the vaccine caused the 
disease. This has frequently resulted in the payment of remu-
neration to the owners, since there is no practical way for the 
vaccine company to provide evidence to the contrary. 
Several CPV vaccine preparations have been proposed: 
CPV was first isolated in 1978 and was named "CPV-2" to 50 U.S. Pat. Nos. 4,193,990 and 4,193,991 to Appel et al., 
describe heterotypic and inactivated ("killed") virus vac-
cines, respectively, in which the exemplary vaccine afforded 
protection against the original CPV. 
distinguish it from parvovirus canine Minute virus (CMV or 
CPV-1 ). CPV-2 is generally believed to be a genetic variant of 
feline panleukopenia virus (FPV) or of the miuk enteric virus 
(MEY), and is genetically and antigenically very closely 
related to parvoviruses that infect minks, foxes, raccoons, and 
other carnivores. The CPV capsid contains a single-stranded 
DNA genome of about 5200 bases with only two open read-
ing frames, although at least four proteins are encoded due to 
alternative mRNA splicing. Parvovirus capsid is made up of 
two viral proteins (VP), VP! and VP2, with VP2 being the 
major immunogenic parvovirus capsid protein. A genetic 
variant of the original CPV isolate was identified in 1979-
1980 and was named CPV type 2a. In the mid-1980's, yet 
another variant, type 2b, was identified, and since then, types 
2a and 2b appear to have completely displaced the original 
CPV-2. Current vaccines are directed against only the 2a and 
2b variants, yet the 2a variant is no longer detected in the 
U.S. Pat. No. 4,303,645 to Carmichael et al., describes a 
55 vaccine comprising an attenuated CPV produced by pro-
longed serial passage of the virus in non-oncogenic cell lines. 
The exemplary vaccine also protects against the original CPV 
isolate. 
U.S. Pat. No. 4,971,793 to Wood et al., and U.S. Pat. No. 
60 5,882,652 to Valdes et al., both describe recombinant subunit 
vaccines comprising the CPV VP-2 protein produced in 
recombinant baculovirus. The VP-2 protein is of no specified 
type or subtype. 
U.S. Pat. No. 5,885,585 to Parrish et al., describes a CPV 
65 vaccine comprising an attenuated form of a 2b variant. 
Due to the ability of the CPV virus to mutate and develop 
new antigenic variants, there is an ongoing need to monitor 
US 8,609,404 B2 
3 
the genetic makeup of CPV variants and to develop vaccines 
and diagnostic tests that reflect current CPV variants. 
SUMMARY OF THE INVENTION 
4 
variant" or as "major American 2c". The sequence of this 
variant is set forth in SEQ ID NO: 3. 
2cll440 (also referred to herein as is a newly discovered 2c 
CPV variant in which the codon encoding position 440 of the 
The present invention provides updated vaccines for pre-
venting CPV infection, and diagnostic methods for detecting 
new and emerging CPV variants. The vaccines and diagnostic 
methods are based on the discovery of previously unknown 
and previously unappreciated CPV variants, and take into 
account the emergence of mutant forms of the virus for which 
prior vaccine formulations and diagnostics are inadequate. 
The vaccines of the present invention provide protection 
against emerging forms of CPV, and the diagnostics provide 
the ability to detect the newly evolved forms of the virus, both 
of which capabilities were previously unavailable. In particu-
lar, new rare variants are useful as "marker" variants in vac-
cines. Use of the marker variant makes possible forensic 
investigations of whether or not disease symptoms in an ani-
mal vaccinated with the marker variant are caused by the 
vaccine, or by another strain of CPV. 
5 VP2 protein is GCA, rather than ACA, which results in a 
change in the amino acid sequence from threonine (ACA) to 
alanine (GCA) at this position. This variant causes disease in 
vaccinated animals and should be incorporated into new vac-
cine formulations. This variant is currently a minor (19%) 
10 
variant and is also referred to herein as the "minor 2c variant" 
or as "Minor American 2c". The sequence of this variant is set 
forth in SEQ ID NO: 4. 
2cM30M40, a further variant of 2cM40, which, in addi-
15 tion to containing GCA at the codon for position 440, also 
varies from known 2c sequences by having the leucine at 
position 430 encoded by TTA rather than the usual TTG. The 
sequence of 2cM30M40 is set forth in SEQ ID NO: 5. 
All of these CPV variants were detected by polymerase 
The new vaccine formulations include whole attenuated 
CPV with single-stranded DNA having one or more of the 
following characteristics: 
20 chain reaction (PCR) and isolated in cell culture from CPV 
infected dogs and/or their puppies that had already been vac-
cinated against CPV using conventional commercial vac-
cines. Thus, these newly emerging variants are capable of 
escaping immune surveillance in dogs vaccinated according 
25 to current protocols, whether the variation does ( e.g. 2cll440 
and 2cM30M40 in part) or does not (e.g. 2bM94ll572, 
2M431, 2bM26M84ll546) change in the amino acid 
sequence of the VP2 protein at the indicated positions. In 
addition, currently available diagnostic techniques for field 
2bll494ll572 is a 2b CPV variant which contains at least 
the following changes: the codon encoding VP2 protein posi-
tion 494 is TGC rather than TGT, and the codon encoding 
VP2 protein position 572 is GTC rather than GTA. These 
changes do not result in amino acid changes (both TGC and 
TGT encode cysteine and both GTC and GTA encode valine ). 
Nevertheless, this variant causes disease in animals that have 
been previously vaccinated with conventional, currently 
available vaccines and should be incorporated into new vac-
cine formulations. While the changes at positions 494 and 35 
572 were previously described, they were not appreciated. 
Further, this American isolate may contain other mutations. 
The sequence of 2b is set forth in SEQ ID NO: 1. 
30 
use do not detect the new CPV variants or react poorly, 
leading to decreased sensitivity. The present invention solves 
these problems by providing vaccines and diagnostics that 
take the new variants into account. 
2bM31M94ll572 (also referred to herein as "2bM31") is 
a newly discovered rare 2b CPV variant (e.g. a variant of 40 
2bM94ll572) in which the codon encoding position 431 of 
the VP2 protein is CTG rather than CTA. While this change 
also does not result in an amino acid change, this variant 
nevertheless also causes disease in vaccinated animals and 
may be incorporated into new vaccine formulations. Signifi- 45 
cantly, due to its scarcity, 2bll431 represents an ideal vaccine 
"marker" sequence. The sequence of 2bll431 is set forth in 
SEQ ID NO: 2. 
2bM26M84M94ll54M572 (also referred to herein as 
"2bM26M84ll546") is a newly discovered 2b CPV variant 50 
(i.e. a variant of 2bll494ll572) which contains the same 
changes as 2bll494ll572 and, in addition, has changes at 
positions 426, 484 and 546. Position 426 is encoded by GAC 
(instead ofGAT), position 484 is encoded by GTG (instead of 
GTA) and position 546 is encoded by AAC (instead of AAT). 55 
These changes do not result in amino acid changes (both GAC 
and GAT encode asparagine, both GTG and GTA encode 
valine, and bothAAC andAAT encode asparagine. Neverthe-
less, this new variant, which was isolated from animals that 
have been previously vaccinated with conventional, currently 60 
available vaccines, is very cytopathic and should be incorpo-
rated into new vaccine formulations, and may be utilized as a 
marker vaccine as described below. The sequence of 
2bM26M84ll546 is set forth in SEQ ID NO: 6. 
American (or United States) 2c is the first 2c variant iso- 65 
lated in the United States and is the predominant (81%) 2c 
variant. This variant is also referred to as the "major 2c 
The invention further provides a method of propagating 
canine parvovirus, particularly the variants described herein, 
which do not produce a cytopathic affect (CPE) or produce 
only a mild CPE, when cultured in CRFK cells alone. The 
method comprises the step of culturing the canine parvovirus 
in a mixture of Crandall Reese feline kidney (CRFK) cells 
and Vero cells in a suitable medium. The step of culturing is 
carried out under conditions that allow the canine parvovirus 
to propagate to titers higher than those attained when the CPV 
is cultured in CRFK cells alone. 
The invention further provides a parvovirus vaccine com-
prising one or more CPV variants. The level of neutralization 
of the one or more CPV variants is at least 4-fold lower than 
the level of neutralization of one or more CPV variants 
selected from the group consisting of CPV-2, CPV-2a, CPV-
2b and CPV-2c, as determined using serum from an animal 
vaccinated with a vaccine comprising one or more of CPV 
variants CPV-2, CPV-2a, CPV-2b and CPV-2c. In some 
embodiments, the levels of neutralization are determined by a 
serum neutralization assay and expressed as a neutralization 
titer. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Exemplary 2bll494ll572 sequence (the nucleic 
acid sequence set forth in SEQ ID NO: 1) in which the codon 
for position 494 is TGC and the codon for position 572 is 
GTC. The nucleic acid sequence encoding amino acids 426 to 
572 of the VP2 protein is shown. 
FIG. 2. An exemplary 2bll431 sequence (the nucleic acid 
sequence set forth in SEQ ID NO: 2) in which the codon for 
position 431 is CTG. The nucleic acid sequence encoding 
amino acids 426 to 572 of the VP2 protein is shown. 
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FIG. 3. The nucleic acid sequence encoding amino acids 
426to 572 (the nucleic acid sequence set forth in SEQ ID NO: 
3) of the major American 2c VP2 protein is shown. 
FIG. 4. An exemplary 2cM40 (minor American 2c) 
sequence (the nucleic acid sequence set forth in SEQ ID NO: 5 
4) in which the codon for position 440 is GCA instead of 
ACA, encoding alanine instead of threonine. The nucleic acid 
sequence encoding amino acids 426 to 572 of the VP2 protein 
is shown. 
FIG. 5. An exemplary 2cll430ll440 sequence (the nucleic 10 
acid sequence set forth in SEQ ID NO: 5). 
FIG. 6. Putative folded structure associated with the 2c 
variant. 
6 
Nevertheless, it was not previously appreciated that these 
changes allow the virus to evade immune clearance in hosts 
vaccinated with currently available vaccines, as described 
herein. This variant is depicted in FIG. 1, where a portion of 
a 2b (i.e. 426=GAT) VP2 gene encoding amino acids 426 to 
572 is shown. The two mutant codons (494 and 572) are 
shown in bold and underlined. 
2) 2bll431 is a rare 2b CPV variant in which contains a 
change from CTA to CTG at the codon encoding position 431. 
The original 2bM31 isolate also included the 2bM94ll572 
mutations and is hence 2bll431ll494ll572. However, the 
invention encompasses any CPV sequence (2a, 2b or 2c) that 
includes CTG at the codon encoding position 431 of the VP2 FIG. 7. Putative folded structure associated with the 
2bM31 variant. 
FIG. 8. Putative folded structure associated with the 
2cM30M40 variant. 
FIG. 9. An exemplary 2bM26M84M94ll54M572 
sequence (the nucleic acid sequence set forth in SEQ ID NO: 
6). 
15 protein. This mutation does not result in an amino acid change (CTA and CTG both encode Leu) but, due to its scarcity, 
2bll43) represents an ideal vaccine "marker" sequence for 
forensic purposes. This aspect of the invention is discussed in 
detail below. This variant is depicted in FIG. 2, where a 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS OF THE INVENTION 
20 portion of a 2b (i.e. 426=GAT) VP2 gene encoding amino 
acids 426 to 572 is shown. The three mutant codons (431,494 
and 572) are shown in bold and underlined. 
The present invention provides CPV vaccines and diagnos- 25 
tics, the compositions of which include newly discovered 
variants that reflect the evolutionary trends of CPV. Each of 
the variants was isolated from a dog that had already been 
vaccinated for CPV, but which nevertheless contracted CPV 
and became ill. Thus, in order to stop or curtail the spread of 30 
CPV, these new variants may be incorporated into vaccine 
protocols. Further, as described in detail below, the identifi-
cation of these variants has led to the discovery of a hyper-
variable region in the CPV genome. 
The discovery of the variants described herein has led to the 35 
identification of a crucial hypervariable (HPV) region of the 
CPV genome. In the past, only nucleotides at positions 1276 
to 1277 have been considered important. However, the epi-
demiological discoveries described herein have shown that 
the critical HPV region actually falls almost in the middle of 40 
the CPV genome from position 1275-1326 of the complete 
VP2 gene. This HPV region encompasses at least two critical 
hypervariable codons, codons 426 and 440 of the VP2 gene. 
Preferably, the hypervariable region comprises the region 
beginning one nucleotide before codon 426 through codon 45 
440. Without being bound by theory, it is likely that the 
biological significance of this HPV region is related to the 
thermodynamic stability of the structures that are formed by 
the sequence, as discussed more fully below. 
3) American 2c is the first 2c variant isolated in the United 
States. The significant emergence of this variant was previ-
ously unappreciated (see FIG. 3). 
4) 2cll440 is a 2c CPV variant in which the codon for 
position 440 of the VP2 protein is GCA, rather than ACA. 
This mutation results in an amino acid change from Thr to Ala 
at position 440. Further, this mutant was also isolated from a 
previously vaccinated dog that nevertheless fell ill with CPV. 
Therefore, this variant sequence should be incorporated into 
new CPV vaccine and diagnostic preparations. This variant is 
depicted in FIG. 4, where a portion of a 2c VP2 gene (i.e. 
426=GAA) encoding amino acids 426 to 572 is shown. The 
mutant codon ( 440) is shown in bold and underlined. Codons 
494 and 572 are underlined for reference. 
5) 2cM30M40, a further variant of 2cM40, which, in 
addition to containing GCA at the codon for position 440, 
also varies from known 2c sequences by having the leucine at 
position 430 encoded by TTA rather than the usual TTG. This 
variant is depicted in FIG. 5. 
6) 2bll426ll484ll494ll546ll572 is a variant of 
2bll494ll572 which contains further changes at pos1t10ns 
426, 484 and 546. Position 426 is encoded by GAC instead of 
GAT, position 484 is encoded by GTG (instead of GTA) and 
position 546 is encoded by AAC (instead of AAT). While 
these changes do not result in amino acid changes (position 
426 is asparagine, position 484 is valine and position 546 is 
asparagine in the variants, this new variant is extremely cyto-
The six variants are as follows: 
1) 2bM94ll572 is a 2b CPV variant in which the codon for 
position 494 of the VP2 protein is TGC rather than TGT and 
the codon for position 572 of the VP2 protein is GTC rather 
than GTA. Neither of these mutations causes a change in the 
encoded amino acids (Cys at position 494 and Val at position 
572) and these sequences have previously been described. 
50 pathic and should be incorporated into new vaccine formula-
tions. While this isolate has the same amino acid sequence as 
CPV-2b, the codon GAC at position 426 is extremely rare, 
and this isolate can also be used as a forensic marker vaccine, 
as described below. 
Table 1 provides a s=ary of the sequence changes in 
these variants. 
TABLE 1 
Codons associated with critical amino acids of the VP2 protein in 
current United States CPV variants 
Variant and 
SEQ ID NO, 
2bi\.494L\.572 
SEQ ID NO, 1 
426 
GAT 
Amino acid position and associated codon 
430 431 440 484 494 546 572 
TTG CTA ACA GTA TGC* AAT GTC* 
US 8,609,404 B2 
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TABLE 1-continued 
Codons associated with critical amino acids of the VP2 protein in 
current United States CPV variants 
Variant and Amino acid 12osition and associated codon 
SEQ ID NO, 426 430 431 440 
2bi\.431L\.494L\.572 GAT TTG CTG* ACA 
( "2bM31") 
SEQ ID NO, 2 
2bi\.426L\.484L\.494L\.546L\.572 GAC* TTG CTA ACA 
("2bi\.426L\.484L\.546") 
SEQ ID NO, 6 
American 2c GAA TTG CAT ACA 
( "Major American 2c") 
SEQ ID NO, 3 
2ci\.440 GAA TTG CAT GCA* 
( "Minor American 2c") 
SEQ ID NO, 4 
2ci\.430L\.440 GAA TTA* CAT GCA* 
SEQ ID NO, 5 
* indicates a mutant codon 
While the changes at positions 494 and 572 were previ-
ously described, the emerging predominance and character-
istics ofthis variant were previously unappreciated. All vari-
ants described herein were isolated from dogs ( or their 
offspring) that had already been vaccinated against CPV but 
which became ill and died from CPV. Although the variants 
were first identified in the south-central United States, they 
are believed to be responsible for sporadic reports of vaccine-
resistant parvovirus illness in dogs in other parts of the US as 
well. Variant 2c previously detected in all continents except 
Australia and Africa, has now been detected in 14 states 
(Alabama, Arizona, Arkansas, California, Delaware, Florida, 
Illinois, Kansas, Jew Jersey, Missouri, Oregon, Oklahoma, 
South Carolina, and Texas). Given the history of rapid dis-
semination of previously known CPV variants, one or more of 
these variants should immediately be included in vaccines 
throughout the world in order to halt the spread of these most 
recent iterations of the virus. Further, CPV diagnostic tests 
and methods should be reformulated to take these emerging 
variants into account. 
As described in the Examples section, the onset of disease 
symptoms and death in the vaccinated dogs from which the 
CPV variants of the invention were isolated was extremely 
rapid, indicating the presence of robust escape mutants which 
are not deterred by an immune system response to CPV types 
that are included in current vaccines. This was true not only 
for 2cli.440, which causes a change in the primary sequence of 
the VP protein, but also for 2cli.431, 2bli.494li.572, which do 
not contain amino acid changes in the regions studied. The 
significance of the 2bli.494li.572 codon changes has hereto-
fore been unrecognized, and to our knowledge, there has up 
until now been no proposal to adjust the compositions of CPV 
vaccines and diagnostics to include or take into account these 
emerging variants, as is described herein. Further, 2cli.440, 
2bli.431, and 2bli.426li.484li.546 are novel mutants that have 
not been described previously. 
These variations appear to provide a survival advantage for 
the virus. Without being bound by theory, it is possible that 
the mutant sequences confer an advantage to the virion or to 
the DNA itself at some stage of the viral life cycle ( e.g. 
protection against host nucleases; faster or more efficient 
484 
GTA 
GTG* 
GTA 
GTA 
GTA 
494 546 572 
TGC* AAT GTC* 
TGC* AAC* GTC* 
TGT AAT GTA 
TGT AAT GTA 
TGT AAT GTA 
transcription and/or translation, which could, for example, 
result in different patterns of protein folding; faster or more 
efficient packaging into the virion particle, etc.). For example, 
30 the mutant sequences may confer an advantage in terms of the 
thermodynamics of unfolding when DNA polymerase repli-
cates the CPV DNA. FIGS. 6-8 depict the folded structures of 
the hypervariable region of CPV2c, CPV2bli.431, and 
CPV2cli.430li.440, respectively, which are further described 
35 in Example 3. 
In one embodiment of the invention, a successful, emerg-
ing CPV variant such as CPV2cli.430li.440 can be used as a 
challenge virus to check the value of commercial vaccine 
preparations under experimental conditions. Most older ver-
40 sions of CPV2a and CPV2b are not highly pathogenic to 
dogs, and the newer CPV2c has not been studied. Because of 
the lack of a highly virulent challenge model, up to now it has 
not been possible for vaccine companies to properly assess 
the ability of vaccine preparations to confer protection on 
45 vaccinated animals. The present invention thus also provides 
a method for doing so by exposing vaccinated animals to the 
highly virulent variant CPV2cli.430li.440, and assessing 
whether or not the vaccine protects against disease. 
For each of the variants described herein, the invention 
50 encompasses vaccine preparations and diagnostics that 
include one or more of the variants, and methods of using the 
same. Preferably, such preparations and diagnostics include 
one or more of the novel variants 2cli.440, 2bli.431 and 
2bli.426li.484li.546. Such preparations and diagnostics may 
55 further include 2bli.494li.572 and/or American 2c, and/or 
other known CPV sequences, such as those that are already 
included in current vaccines. In addition, other newly isolated 
viruses with novel sequences, particularly with novel amino 
acid sequences, may or may not be suitable for inclusion in a 
60 new vaccine. In general, the decision to include anew field 
isolate is based on the ability of existing vaccines to elicit 
neutralizing responses to the field isolate in a vaccinated 
animal, and in part on the prevalence of the variant. If a new 
variant is ubiquitous, its antigenic significance should be 
65 determined. One measure of this is antigenic distance. The 
total antigenic distance of a particular CPV isolate can be 
determined by testing the isolate using a functional assay, 
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such as serum neutralization titer and/or a hemagglutination 
assay and/or an indirect fluorescence antibody test. If, accord-
ing to one or more assays, an isolate exhibits poor neutraliza-
tion compared to viral variants already in the vaccine (i.e. if 
the level of neutralization of the new, heterologous isolate is 5 
more than 4-fold lower than the level of neutralization of 
variants already in the vaccine) then the development of a new 
vaccine which includes the new isolate may be warranted. For 
example, when a new CPV variant is isolated, the total anti-
genic distance can be calculated with a serum neutralization 10 
assay, and the results expressed as a neutralization titer. Neu-
tralization titer is the inverse of the highest dilution of the 
serum from a vaccinated animal at which neutralization is 
complete evidenced by a lack of cytopathic effect (CPE) or 
presence of virus. If serum from dogs vaccinated with an 15 
existing CPV vaccine gives, for example a SN titer of 1 :4000 
with a homologous virus and a titer of 1 :200 with a new 
heterologous CPV isolate, then the new isolate should likely 
be included in a CPV vaccine. In other words, if the current 
vaccine does not protect against a common, ubiquitous vari- 20 
ant that is not in the current vaccine, then the variant may be 
with care included in a new vaccine preparation. If the isolate 
is localized in a small geographic area, then a custom or 
autogenous vaccine may be more suitable than a commercial 
vaccine designed for widespread use. The results should also 25 
be confirmed with challenge protection experiments. In chal-
lenge protection experiments, animals are vaccinated and 
then exposed to moderate doses (e.g. 10,000 TCID 50, i.e. 
median tissue culture infective dose) of a variant that is used 
as the challenge virus. If the vaccine provides protection 30 
against the variant, then the variant need not be included in 
vaccine compositions. However, if a vaccinated animal is not 
protected from the variant, the variant may be included in 
vaccine preparations. Further, during the vaccination process, 
not all strains or variants need to be included in the same 35 
10 
2bll426ll484ll546 mutations into one or more of the vaccine 
strains that are used to formulate vaccines. 2bll431 and 
2bll426ll484ll546 are extremely rare, e.g. 2bll431 represents 
only about 1.2% of the variants studied to date and 
2bll426ll484ll546 has been detected in only one variant. 
Therefore, when tissue from a diseased animal that has been 
vaccinated with a 2bM31 or 2bM26M84ll546 variant is 
tested for CPV, if any CPV strain other than 2bll431 or 
2bll426ll484ll54 is detected, it can be confidently concluded 
that the vaccine did not cause the disease. Rather, the other 
detected strains were the likely culprit. Further, these muta-
tions could be detected without extensive sequencing. This 
type of forensic investigation could provide significant sav-
ings to vaccine companies. 
The invention provides vaccine preparations that comprise 
isolated nucleic acid sequences represented by SEQ ID NOS: 
1, 2, 3, 4, 5 and 6 and/or proteins, polypeptides or peptides 
encoded by those sequences, and methods of their use. In 
addition, vaccines with certain variations of these sequences 
are also encompassed. While the sequences represent single-
strand (ss) DNA, the invention also includes corresponding 
double-strand ( ds) DNA, complementary DNA, and RNA of 
any form ( e.g. mRNA, RNA/DNA hybrids, etc.) that is based 
on, derived from or that complements these sequences. Such 
sequences may be either sense or antisense sequences. Fur-
ther, sequences which display at least about 50% homology, 
preferably about 60%, more preferably about 70, 80, or 90% 
homology, or even about 95, 96, 97, 98 or 99% or greater 
homology to SEQ ID NOS: 1, 2, 3, 4, 5 and 6 are also 
contemplated for use in the vaccines. Such sequences may 
differ, for example, by containing alternate codons that 
encode the same amino acid at one or more positions. In 
addition, portions of these sequences which encode antigenic 
regions of the CPVVP2 protein are also contemplated, as are 
sequences which display 70%, or even more preferably about 
80, 90, or 95% or even greater identity (e.g. 96, 97, 98 or 99% 
identity) to such amino acid sequences. Such sequences may 
vary, for example, by containing conservative or non-conser-
vative amino acid substitutions, or deletions ( especially 
injection. It may be preferable, for example, to administer a 
puppy shot that contains one variant at 3 weeks of age, a shot 
that contains a different variant at 7 weeks, and a shot that 
contains yet another variant at 10 weeks. This is in contrast to 
the current practice, in which the same variants are adminis-
tered for all three puppy shots. This current procedure suffers 
from the drawback that existing immunity developed in 
response to an earlier vaccination can neutralize incoming 
CPV viruses delivered in later vaccinations, rendering later 
vaccinations of little or no use. Of note, it is well known that 
some viral pathogens can infect multiple species. In the case 
of CPV, feline and mink viruses have been known to also 
infect dogs. While the inclusion of such viruses in a canine 
CPV vaccine is not advisable, these feline and mink viruses 
should be included in challenge experiments of vaccinated 
animals. 
40 amino or carboxy terminal deletions), or various insertions, 
etc., so long as the resulting protein/peptide is antigenic as 
described herein. Such antigenic regions are preferably at 
least about 10 amino acids in length and encompass one or 
more of positions 426,431,440,484,494,546, 555, and 572 
In particular, variants 2bM31 and 2bM26M84ll546 are 
useful in the preparation of vaccines suitable for forensic 
tracking and detection. As described above, current vaccines 
increasingly fail to protect vaccinated animals against emerg-
ing CPV, The owners of animals that are sickened after vac-
cination tend to blame the vaccine itself for causing disease. 
Because current diagnostic methods are inadequate to differ-
entiate among vaccines strains and emerging strains, vaccine 
manufacturers have no practical defense against such accu-
sations and frequently settle such claims by reimbursing the 
animals owners. This process is very costly for vaccine manu-
facturers. Also, the proximity of codon 431 to codon 426 and 
its location in the hypervariable region of the CPV genome 
also allows only limited sequencing to be done to verify the 
source of the causal CPV agent in a sick dog. This could be 
avoided by incorporating the 2bll431 and/or 
45 of the VP protein. An antigenic region may, however, encom-
pass an entire VP2 gene. 
Further, nucleic acid sequences which hybridize to 
sequences disclosed herein ( or to portions of those 
sequences) under stringent conditions ( especially conditions 
50 of high stringency) are also contemplated. Stringent condi-
tions refer to hybridization conditions which allow a nucleic 
acid sequence to hybridize to a particular sequence. In gen-
eral, high stringent conditions refer to the hybridization con-
ditions which allow a nucleic acid sequence of at least 50 
55 nucleotides and preferably about 200 or more nucleotides to 
hybridize to a particular sequence at about 65° C. in a solution 
comprising about 1 M salt, preferably 6xSSC or any other 
solution having a comparable ionic strength, and washing at 
65° C. in a solution comprising about 0.1 M salt, or less, 
60 preferably 0.2xSSC or any other solution having a compa-
rable ionic strength. These conditions allow the detection of 
sequences having about 90% or more sequence identity. In 
general, lower stringent conditions refer to the hybridization 
conditions which allow a nucleic acid sequence of at least 50 
65 nucleotides and preferably about 200 or more nucleotides to 
hybridize to a particular sequence at about 45° C. in a solution 
comprising about IM salt, preferably 6xSSC or any other 
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solution having a comparable ionic strength, and washing at 
room temperature in a solution comprising about IM salt, 
preferably 6xSSC or any other solution having a comparable 
ionic strength. These conditions allow the detection of 
sequences having up to 50% sequence identity. The person 
skilled in the art will be able to modify these hybridization 
conditions in order to identify sequences varying in identity 
between 50% and 90%. 
The invention also provides various types of recombinant 
vectors and/or expression systems that contain and express 
the nucleic acid sequences disclosed herein ( or portions 
thereof that encode antigenic peptides and/or polypeptides). 
Examples of such vectors and expression systems include but 
are not limited to: various bacterial ( e.g. Escherichia coli) or 
probiotic-based (e.g. Lactobacillus) expression vectors; 
adenoviral vectors, baculovirus, Pichia, and yeast expression 
systems, etc. Such recombinant vectors and expression sys-
tems may be utilized, for example, in vaccine preparations, or, 
alternatively, for other purposes such as for laboratory 
manipulation of the sequences, or for research or diagnostic 
purposes. 
The invention provides immunogenic and/or vaccine com-
positions against canine parvovirus. The compositions com-
prise one or more of nucleic acid sequence SEQ ID NO: 1, 2, 
12 
In addition, vaccine compositions may be tailored for use 
in a particular host. For example, some breeds of dogs may be 
more susceptible to some variants than to others; or the life 
stage of the animal (e.g. puppy vs adult) may predispose an 
5 animal to susceptibility to one or more variants; or when hosts 
other than dogs are to be vaccinated ( e.g. wild life, animals in 
zoos or on game reserves, etc.), the vaccine composition may 
be adjusted to take into account the susceptibility of the 
particular host animal that is to receive the vaccine. For 
10 example, in the development of a challenge model, Chihua-
hua and Labrador retriever breeds tend to be more susceptible 
to CPV. Thus, about 4 logs of the highly virulent CPV-2c 
variant should suffice to induce diarrhea and vomiting in a 
controlled setting. All such host-specific or host-selective 
15 vaccines are encompassed by the present invention. 
In other embodiments, the vaccine composition may be 
adjusted according to the local environment of the vaccine 
recipient. For example, in commercial kennels housing more 
than 100 dogs, where the risk of contagious infection is high, 
20 vaccination with relatively expensive preparations containing 
variant 2bll431ll494ll572 and/or variant 
2bM84M94ll54M572 in combination with both the major 
and minor American CPV 2c variants may be preferred. How-
ever, in smaller kennels ( e.g. with less than 25 dogs) or in 
25 homes with one or only a few dogs, where the risk of exposure 
is lower, vaccination with less expensive vaccines containing 
variants 2bM31M94ll572 and/or 2bM84M94ll54M572 
together with only the major American 2c variant may suffice. 
3, 4, 5 and 6, or portions of those sequences which encode 
antigenic peptides or polypeptides (antigenic regions), e.g. 
portions of the sequence that include one or more of the 
codons for positions 426, 430, 431, 440, 484, 494, 546, 555, 
and 572. Preferably, at least sequences containing SEQ ID 30 
NO: 2 or SEQ ID NO: 4 or SEQ ID NO: 5 or SEQ ID NO: 6, 
When deciding which vaccine compositions to use, the risk of 
animals contracting the disease should be weighed against 
cost and the ability to molecularly monitor and assess the 
or portions thereof which encode antigenic regions, will be 
included. 
Those of skill in the art will recognize that vaccine com-
positions may also be varied according to projected use. In 
other words, the particular components (variants) included in 
the vaccine may be varied according to any of several param-
eters to create specially designed vaccine preparation. For 
example, vaccines can be designed to include only those 
variants that have been detected in a particular geographical 
location. For example, the 2a variant is no longer detected in 
the United States and thus vaccine manufacturers may choose 
not to include this variant in vaccine formulations to be used 
in the US. US vaccines might contain, for example, only CPV 
2c and CPV 2b variants. In contrast, at present, 2a is the only 
CPV variant in Australia. Thus, a vaccine composition des-
tined for use in Australia might include only the 2a variant. 
Recommended vaccines for Europe might include, for 
example, 2c and 2b variants, while a vaccine composition for 
Asia might include 2a and 2b. All such geographically tai-
lored vaccines are encompassed by the present invention, and 
may be varied over time as the pattern of variant distribution 
changes. A further consideration with such geographically 
specific vaccines is that modified live virus vaccines contain 
high amounts of vaccine viral antigen. Thus, if a dog vacci-
nated with a variant is relocated to an area where that variant 
does not exist, it is preferable to quarantine the animal for at 
least about one month before release into the new environ-
ment. Otherwise, the variant may be released into the new 
location. For example, dogs vaccinated with a 2c variant 
should be quarantined prior to release in e.g. Australia. After 
the one month period, viral shedding should cease. Even 
though the shed virus is attenuated, its presence can confound 
attempts to monitor viral epidemiology, and could afford the 
opportunity for native viruses to recombine with the shed 
virus, resulting in introduction of the more virulent mutation 
into the local population. 
presence of CPV variants in the future. 
In yet another facet, the invention provides a vaccine strat-
egy for avoiding maternal antibody interference with vaccine 
35 immunity induction in puppies. Rather than use a single 
preparation of vaccine for adults and puppies, puppies can be 
vaccinated with a series of vaccines that differ antigenically. 
In other words, the initial puppy vaccine would contain vari-
ants that might differ from those that had been administered to 
40 the mother, and subsequent puppy booster shots would 
include yet other iterations of the vaccine. In this way, abroad 
spectrum of antibodies would be built up incrementally. The 
route of vaccination can be modified to overcome some vac-
cination limitations of, like shedding virus after parenteral 
45 immunization. For example, by using a supra-lingual vacci-
nation route employing needle-less technology, immunity 
may be induced but shedding in the feces may be prevented. 
Several methods of making vaccines suitable for vaccina-
tion against CPV are known in the art. See, for example, U.S. 
50 Pat. Nos. 4,193,990 and 4,193,991 to Appel et al., U.S. Pat. 
No. 4,303,645 to Carmichael eta!., U.S. Pat. No. 4,971,793 to 
Wood et al.; U.S. Pat. No. 5,882,652 to Valdes et al., and U.S. 
Pat. No. 5,885,585 to Parrish et al., each of which offers 
variations of suitable vaccine-formulating strategies. The 
55 complete contents of each of these patents are hereby incor-
porated by reference. Generally, to manufacture a vaccine, a 
viral vector containing the described nucleic acid sequences 
( e.g. ssDNA naturally occurring within a virus, or ssDNA or 
other equivalent form genetically engineered into a non-na-
60 tive viral vector (e.g. dsDNA, ss or dsRNA, RNA-DNA 
hybrids, etc.) will be employed. Examples include CPV (or 
other) viruses that are "killed", inactivated or otherwise 
attenuated so as to not cause severe disease symptoms in the 
animal to which it is administered, together with a suitable 
65 physiological carrier. Preferably, no disease symptoms will 
occur as a result of administration. However, those of skill in 
the art will recognize that many effective vaccine composi-
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tions cause some discomfort or relatively minor distress upon 
or after administration. However, the benefits of being pro-
tected against full-blown disease far outweigh this possibility. 
14 
may contain minor amounts of auxiliary substances such as 
wetting or emulsifying agents, pH buffering agents, and the 
like. If it is desired to administer an oral form of the compo-
sition, various thickeners, flavorings, diluents, emulsifiers, As an alternative, a heterotypic virus that does not naturally 
infect or that does not normally cause disease in the animal 
being vaccinated may be utilized. 
5 dispersing aids or binders and the like may be added. The 
composition of the present invention may contain any such 
additional ingredients so as to provide the composition in a 
form suitable for administration. The final amount of the 
The attenuated virus may be a CPV that naturally contains 
the nucleic acid sequence( s ), or the virus (CPV or other virus) 
may be recombinant in that the nucleic acid sequence is 
inserted into the virus by genetic engineering. In the case of 10 
recombinant vaccines, the nucleic acid sequences may be 
incorporated into viruses other than CPV to form heterotypic 
recombinant vaccines. Examples of such viruses include but 
are not limited to FPV, various herpesviruses, non-pathogenic 
"orphan viruses", enteric viruses such as enterovirus, etc. In a 15 
preferred embodiment, the virus is alive, attenuated (modi-
fied) high titer CPV, and the nucleic acid is ssDNA. 
Preferably, such a preparation will also contain nucleic 
acid sequences encoding antigenic regions of other CPV vari-
ants, e.g. the 2, 2a, 2b and/or 2c variants, and any other CPV 20 
variants that may be subsequently identified and considered 
translatable nucleic acid in the formulations may vary. How-
ever, in general, the amount will be from about 1-99%. The 
compositions may further comprise an adjuvant, suitable 
examples of which include but are not limited to Seppic, Qui! 
A, Alhydrogel, etc. 
The immunogenic/vaccine preparations of the present 
invention may be administered by any of many suitable 
means which are well known to those of skill in the art, 
including but not limited to by injection, orally, intranasally, 
by ingestion of a food product containing the antigen, etc. 
However, in preferred a embodiment, the mode of adminis-
tration is by injection. In addition, the compositions may be 
administered alone or in combination with other medica-
ments or immunogenic compositions, e.g. as part of a multi-
component vaccine. Further, administration may be a single 
event, or multiple booster doses may be administered at vari-
ous timed intervals to augment the immune response. In addi-
tion, administration may be prophylactic, i.e. before exposure 
to the virus has occurred, or is suspected to have occurred, or 
after the fact, i.e. after a known or suspected exposure, or 
therapeutically, e.g. after the occurrence of disease symptoms 
to be useful. However, given the wide distribution of vaccine 
compositions containing only the 2a and 2b variants, it may 
also be beneficial to produce vaccine compositions contain-
ing only one or more of the variants disclosed herein, for use 25 
in conjunction with and to complement the effects of the 
known 2a-2b vaccines. Further, such vaccines may be admin-
istered with vaccines against other disease causing entities, 
either as separate compositions, or together in a single com-
position. 30 associated with viral infection. 
The exact form of the vaccine may vary. In one embodi-
ment, the vaccine is comprised of attenuated CPV viruses 
which contain nucleic acid sequences as disclosed herein. 
Preferably the vaccine is multivalent and also includes attenu-
ated CPV 2, 2a, 2b, and/or 2c type viruses. Alternatively, a 35 
single virus may be genetically engineered to contain nucleic 
acids encoding proteins ( e.g. VP2 proteins, or antigenic por-
tions thereof) from two or more variant types, i.e. recombi-
nant chimeric CPV s having genomic regions from two or 
more regions of VP2 can be constructed by recombinant 40 
technology by exchanging DNA regions from two or more 
CPV s, as is known by those of skill in the art. 
Other forms of the vaccine are also contemplated. For 
example, "empty" virion particle vaccines (without nucleic 
acid) are also contemplated, as are vaccines comprising anti- 45 
genie virion or other CPV proteins that are not assembled into 
a capsid. In these cases, the proteins in the vaccine prepara-
tion are encoded by one or more of SEQ ID NO: 2, SEQ ID 
NO:4 and SEQ ID NO: 6, or alternatively, shorter antigenic 
regions are encoded by portions of SEQ ID NO:2 and/or SEQ 50 
ID NO:4 and/or SEQ ID NO: 5 and/or SEEQ ID NO: 6. 
Proteins encoded by SEQ ID NO: 1 and/or SEQ ID NO: 3, 
and/or antigenic regions encoded by portions of SEQ ID NO: 
1 and/or SEQ ID NO: 3 may also be included. 
Other suitable vaccine components, e.g. pharmacologi- 55 
cally acceptable carriers, are well-known to those of skill in 
the art, as is the preparation of such compositions for use as 
vaccines. Typically, such compositions are prepared either as 
liquid solutions or suspensions, however solid forms such as 
tablets, pills, powders and the like are also contemplated. 60 
Solid forms suitable for solution in, or suspension in, liquids 
prior to administration may also be prepared. The preparation 
may also be emulsified. The active ingredients may be mixed 
with excipients which are pharmaceutically acceptable and 
compatible with the active ingredients. Suitable excipients 65 
are, for example, water, saline, dextrose, glycerol, ethanol and 
the like, or combinations thereof. In addition, the composition 
Upon administration of the preparation, the nucleic acid 
sequences of the invention are expressed within the host 
animal to whom the vaccine has been administered, and the 
host animal mounts an immune response to the antigenic 
proteins ( or portions thereof) encoded by the nucleic acid. 
Preferably, the immune response that is elicited is a protective 
immune response. In some embodiments, the attenuated virus 
retains the ability to replicate within the host, although this is 
not strictly necessary. 
The invention provides methods of preventing the symp-
toms of CPV infection in a manimal in need thereof. Gener-
ally, the CPV vaccines are administered to provide active 
immunity in puppies and/or adult dogs. The method involves 
administering to the manimal an immunogenic and/or vac-
cine composition comprising a nucleic acid that includes the 
sequence represented by at least one of SEQ ID NO: 2 and 
SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6, or portions 
thereof which encode antigenic regions ofVP2, and prefer-
ably comprising sequences represented by one or more of 
SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 
4, SEQ ID NO: 5 and SEQ ID NO: 6, or portions thereof 
which encode antigenic regions of VP2. In a preferred 
embodiment, the preparation also includes nucleic acids 
encoding other clinically relevant CPV variants, preferably 
the 2a and 2b variants, and, optionally, the original CPV2. 
Administration of the composition results in the elicitation of 
an immune response by the recipient. Preferably, the immune 
response is protective against future exposure to CPV, and 
either eliminates disease symptoms entirely, or ameliorates 
disease symptoms to a milder level than would be experi-
enced without vaccination. 
In a preferred embodiment of the invention, the animals 
that are vaccinated using the vaccines of the invention are 
domestic dogs, including both adult dogs and puppies. How-
ever, the vaccination of other potential CPV hosts is also 
contemplated. Other potential hosts include other canids such 
as wild canids (e.g. wolves, wild dog species, etc.), cats 
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(including domestic cats and kittens, and larger species of 
cats, whether domesticated or wild), mink, red panda, foxes, 
lion and tigers, etc. While the vaccines will of course be used 
in domestic animals, wild or partially domesticated animals 
may also benefit from such vaccination, e.g. animals in zoos 5 
or protected areas, parks, in research facilities, etc. Any ani-
mal that can host the CPV and CPV variants, whether or not 
the virus causes disease symptoms in the host, may benefit by 
being vaccinated by the vaccine preparations provided herein. 
Vaccination of animals that are asymptomatic upon infection 10 
by the virus (i.e. silent carriers) would be beneficial in order to 
curtail the spread of the virus to more susceptible populations. 
The invention also provides antibodies that bind specifi-
cally or selectively to antigenic determinants or antigenic 15 
regions of proteins of the type 2bll494ll572, 
2bM26M84ll546, 2M431, 2cM40 and or Anlerican 2c 
variant CPV s. Such differential antibodies may be polyclonal 
or monoclonal, although monoclonal antibodies are generally 
preferred. Monoclonal antibodies will be prepared by inject- 20 
ing the variants ( either in protein form, or nucleic acids 
ancoding the proteins) in mice. After 3 boosters, the spleens 
will be harvested and fused with myeloma cells. The mono-
clonal antibodies producing clones will be screened by 
ELISA, HA-HI, and indirect fluorescent antibody test. The 25 
clones that react with 2bM94ll572, 2bM26M84ll546, 
2bll431, 2cll440 and/or Anlerican 2c genotypes will be saved 
for development ofCPV diagnostic assays. Polyclonal anti-
bodies may be prepared by injecting one or more peptides that 
span the amino acid codons that are preferred antigenic tar- 30 
gets of the 2M494ll572, 2M426M84ll546, 2M431, 
2cll440 and/or Anlerican 2c variants e.g. into rabbits. 
The invention also provides diagnostic kits for the detec-
tion of the CPV variants described herein, and, optionally, of 
other CPV variants as well ( e.g. CPV2, 2a and 2b ). Such kits 35 
include oligonucleotide primers specific for amplifying ( e.g. 
by polymerase chain reaction) the nucleic acid sequences 
disclosed herein. Alternatively, such kits may include anti-
bodies (e.g. monoclonal or polyclonal) that bind selectively 
or specifically to unique antigenic determinants displayed by 40 
the variants, and, optionally, other CPV variants as well ( e.g. 
CPV2, 2a and 2b ). 
In a further aspect of the invention, a new method for 
culturing CPV in vitro is provided. The method involves 
culturing the virus in a mixed cell culture of 1) cells that are 45 
known to be susceptible to infection by CPV, and 2) Vero 
cells, in a suitable medium. In a preferred embodiment, the 
cells that are susceptible to infection by CPV are CRFK cells. 
However, other types of such cells may also be used, includ-
ing but not limited to: A 72 canine fibroma-derived cells; cells 50 
derived from CRFK cells such as Nordisk Laboratory feline 
kidney (NLFK) cells; feline tongue cells such as F e3 T g cells; 
feline lung cells such as AK-D cells; feline lymphoma cell 
lines such as 3201; canine T-cell lines such as CT 45-S; canine 
thymus epithelial cells lines such as Cf2Th, etc. Moreover, a 55 
variety of feline and canine cell lines, as well as instructions 
for culturing them, may be obtained from theAnlerican Type 
Culture Collection in Manassas, Va. 
These cell lines can be propagated, together with Vero 
cells, in a variety of media which are known to those of skill 60 
in the art. For example, CT 45-S cells can be cultured in RPMI 
1640 media; AK-D, Fe2lu and Cf2Ths cells may be cultured 
in Dulbecco's minimal essential media (MEM) with 10% 
fetal bovine serum (FBS); for 3201, NLFK, CRFL, A72 and 
Fc3 Tg cells, McCoy's SA and Leibowitz L15 with 5% FCS 65 
and be used. Typically, the cell lines are incubated together for 
4-5 days at 37° C. 
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EXAMPLES 
Introduction 
Canine parvovirus (CPV) infection is the most serious and 
prevalent disease of dogs, and is the most common cause of 
diarrhea in puppies. Although vaccines against CPV are avail-
able and widely used, several recent outbreaks of CPV in 
vaccinated dogs have occurred. For example, kennel owners 
in South Central United States have observed high rates of 
puppy mortality due to CPV infection in spite of vaccination. 
CPV is a single-stranded DNA virus that has a high rate of 
mutation and the ability to change its host range and tropism. 
Commercial vaccines that are currently available typically 
contain only the CPV2, CPV2a, and CPV2b variants. During 
our analysis of samples from CPV vaccinated dogs with overt 
symptoms of parvovirus infection, we observed functional 
changes in CPV detection by current CPV diagnostic tests 
and failure of the current kits to detect the field virus, indi-
cating possible evolution of CPV beyond the 2a and 2b sub-
types. Further investigations resulted in the identification of 
two variants ofCPV, namely 2bll494ll572 andAnlerican 2c. 
The isolates are associated with enhanced virulence and 
broader tissue tropism than is observed with heretofore cul-
tured CPV isolates. In addition, it appears that the new CPV 
isolates cause yellow mucous diarrhea instead of hemor-
rhagic diarrhea caused by CPV-2 genotypes in the past. Con-
sistent with other reports, the 2bll494ll572 variant has two 
codon changes. TheAnlerican 2c variant has been previously 
detected in Italy, Spain and Vietnam, but has not been previ-
ously detected in the United States. 
Materials and Methods 
Fecal Samples were Received by the Oklahoma Animal 
Disease Diagnostic 
Laboratory by Federal Express over ice packs (about 4-5° 
C.). A minimum of 2-5 grams of feces or 2-5 ml of liquid 
diarrhea stools were received. The fecal samples are generally 
tested the same day by CPV Enzyme Linked Immunosorbent 
Assay (ELISA)(s) that are commercially available. We 
receive intestinal loops (about 2-3 pieces) from different 
regions of the gut for fluorescent antibody test (FAT) or 
immunohistochemistry (IHC). Sometimes, we received 
pieces of the tongue for FAT or IHC or polymerase chain 
reaction (PCR) for CPV examination. These specimens are 
received cool over ice packs by FedExp. Many CPV cases 
have a history of testing negative for CPV by field diagnostic 
kits (Assure, Synbiotics, CA; or IDEXX, Bar Harbor, Me.). 
Histopathology was performed on the intestines of puppies 
and adult dogs with a history compatible with CPV. The 
history included bloody or mucous diarrhea, and death. Fresh 
and formalin-fixed intestinal tissues were examined for 
lesions compatible with CPV: crypt dilatation and necrosis, 
and loss of intestinal villi. 
Fluorescent antibody (FAT) test was used to screen the 
intestines for CPV antigen. The intestinal sections 6-8 
micrometers in thickness were fixed with acetone and air 
dried. Anti CPV conjugate labeled with FITC was added and 
sections were incubated for 30 min at 3 7° C. After washes, the 
sections were counterstained with trypan blue. The sections 
were examined by fluorescent microscopy: CPV positive 
cells stain apple green and CPV negative cells stain brick red 
with a FAT test. 
Formalin-fixed sections submitted for histopathologywere 
examined by immuno-histochemistry for CPV antigen. 
PCR followed by sequencing were carried out on fecal 
samples and scrapings of the CPV positive or suspected intes-
tinal samples, as described by Desario et al., 2005. A portion 
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of the viral protein gene was amplified by PCR. The amplified 
PCR product was detected by agarose gel electrophoresis and 
eluted from the gel for sequencing. 
Sequences were subjected to analysis by the BLAST pro-
gram that compares the results with a vast collection of 5 
sequences that have been deposited in the GenBank. All the 
sequences were identified as similar to canine parvovirus. 
Example 1 
10 
Failure of Current CPV Diagnostic Tests 
18 
nant CPV variants, and signal the need to incorporate these 
variants into CPV vaccine preparations. 
Other variants were identified in a similar manner. In par-
ticular, the novel variant 2bM26M84ll546 (SEQ ID NO: 6), 
which is highly cytopathic, has also been identified in this 
manner. 
Example 3 
Determination of Variant Secondary Structure and 
Associated Energy 
The virulence of viral pathogens is known to be associated 
with secondary structural elements in the viral genome (Pel-
lerin et al., 1994. Virology 203: 260-268). The folding pat-
terns of hypervariable regions of variants 2c, 2bll431 and 
2cll430ll440 were assessed using the "mfold" DNA folding 
program at the web site located at mfold.burnet.edu.au on the 
World Wide Web. The results are shown in FIGS. 6-8, which 
Fecal samples were analyzed as described above, and all 
samples were positive using the standard criteria of: charac-
teristic lesions as determined by histopathology, fluorescent 15 
antibody test results, and immuno-histochemistry results. 
Nevertheless, upon testing of the same samples using com-
mercial diagnostic tests, the results showed that the tests were 
unreliable for CPV field diagnosis of these samples, failing to 
detect 33-50% ofCPV positive cases. 20 depict the folding patterns and associated energy levels for 
each variant. As can be seen, the secondary structure of the 
region is maintained and the energy levels for unfolding can 
change. 
Most of these CPV isolates were obtained from kennels 
that are currently using commercial CPV vaccines according 
to the vaccine label but still experiencing CPV outbreaks and 
mortality. This lack of protection is likely due to antigenic 
variation in the newly emerging CPV isolates. This epidemio- 25 
logical field observation over many CPV cases (n-500) sig-
nals the need to incorporate these new CPV variants into 
commercial CPV vaccines. 
Example 2 
Sequencing ofCPV Isolates: Identification of 
2bM94ll572 Variant and American CPV2c Isolate 
30 
Example 4 
Development and Testing of a New Multivalent 
Vaccine Against CPV 
A new multivalent vaccine that is protective against newly 
emerging CPV variants is developed. The vaccine includes 
one or more attenuated CPV viruses of types CPV2b, 
2M494ll572 (SEQ ID NO 1), 2M431 (SEQ ID NO 2), 
2M426M84ll546 (SEQ ID NO 6), American 2c (SEQ ID 
The failure of vaccines and diagnostic kits is generally 
considered to be epidemiological evidence of viral evolution. 
Therefore, the presence of new CPV variants in the samples 
being studied was suspected. To confirm this, PCR-sequenc-
ing of a portion of the viral protein VP2 was carried out for 
viruses isolated from the fecal samples, and the results were 
compared to known VP2 sequences using computer software 
programs and/or manual alignment. 
35 NO 3), 2cM40 (SEQ ID NO 4), and, optionally, CPV2. In 
other words, in this novel vaccine, CPV2b is replaced by 
2bM94ll572 and/or 2bM26M84ll546, the variants that have 
newly been discovered to be emerging as the dominant geno-
type. The presence of CPV2, which appears to no longer be a 
40 threat, is optional. 
The results confirmed the presence of two newly emerging 
CPV types in the samples: 1) a variant of 2b which was 
denominated 2bM94ll572; and 2) American 2c, which had 45 
not been previously reported in the United States. The DNA 
sequences encoding portions of the VP2 proteins of the two 
variants are presented in FIG. 1 (2bM94ll572, SEQ ID NO: 
Animals vaccinated with the multivalent vaccine are pro-
tected against developing symptoms of parvovirus infection 
by the variants used to prepare the vaccine. 
Example 5 
Novel Mixed Cell Culture Methods for CPV 
Propagation 
CPV is typically grown in a cell cultures containing only a 
single type of cell such as the Crandall feline kidney (CRFK) 
cell line. 
An improved method of culturing CPV has been devel-
oped. According to the new method, CPV is cultivated in an 
equal mixture of CRFK and Vero cells in minimum essential 
medium (MEM). Both the cell lines were plated and samples 
were inoculated one hour after plating. At this stage the cells 
were attached but still in the early stages of cell division. The 
new cell culture method produced detectable cytopathic 
effects more rapidly than when the CPV was cultivated with 
CRFK cells alone. Moreover, high titers of CPV production 
were maintained in the mixed cell culture for 3 serial pas-
sages. 
While the invention has been described in terms of its 
1) and FIG. 3 (American 2c, SEQ ID NO: 3).A comparison of 
these sequences to a known CPV 2 reference sequence 50 
revealed that, in 2bll494ll572, a change in codons 494 and 
572 had taken place. The usual CPV 2 codon at 494 is TGT 
but in 2bM94ll572 codon 494 is TGC. Similarly, the usual 
codon at position 572 in CPV2 isolates is GTA but in 
2bll494ll572 this codon is GTC. These changes do not result 55 
in changes in the amino acid sequence of the VP2 protein. 
However, it is likely that the changes confer advantages to the 
2bll494ll572 variant in one or more phases of its life cycle, 
e.g. in replication, transcription or translational efficiency. 
Significantly, the presence of the American 2c variant in the 60 
samples is the first report of this CPV variant in the United 
States and is likely a harbinger of its emergence as a dominant 
variant. About 50% of the cases of vaccine failure were due to 
the presence of the CPV2bll494ll572 and 50% were attribut-
able to CPV2c or CPV2cM30M40. 65 preferred embodiments, those skilled in the art will recognize 
that the invention can be practiced with modification within 
the spirit and scope of the appended claims. Accordingly, the 
These findings demonstrate the emergence of2bll494ll572 
(SEQ ID NO: 1) and American 2c (SEQ ID NO: 3) as domi-
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present invention should not be limited to the embodiments as 
described above, but should further include all modifications 
and equivalents thereof within the spirit and scope of the 
description provided herein. All United States patents, patent 
applications, and other references cited herein are hereby 5 
incorporated by reference. 
Desario, Constantina, N. Decaro, M. Campolo, A. Cavalli, F. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 6 
<210> SEQ ID NO 1 
<211> LENGTH, 441 
<212> TYPE, DNA 
<213> ORGANISM, Canine parvovirus 
<400> SEQUENCE, 1 
gatgataatg tattgctacc aacagatcca attggaggta aaacaggaat taactatact 60 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 120 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtaaat 180 
gcaccatttg tttgtcaaaa taattgccct ggtcaattat ttgtaaaagt tgcgcctaat 240 
ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt aacttactca 300 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc tcatacttgg 360 
aatccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt accaagtaat 420 
attggaggta tgaaaattgt C 441 
<210> SEQ ID NO 2 
<211> LENGTH, 441 
<212> TYPE, DNA 
<213> ORGANISM, Canine parvovirus 
<400> SEQUENCE, 2 
gatgataatg tattgctgcc aacagatcca attggaggta aaacaggaat taactatact 60 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 120 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtaaat 180 
gcaccatttg tttgtcaaaa taattgccct ggtcaattat ttgtaaaagt tgcgcctaat 240 
ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt aacttactca 300 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc tcatacttgg 360 
aatccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt accaagtaat 420 
attggaggta tgaaaattgt C 441 
<210> SEQ ID NO 3 
<211> LENGTH, 441 
<212> TYPE, DNA 
<213> ORGANISM, Canine parvovirus 
<400> SEQUENCE, 3 
gaagataatg tattgctacc aacagatcca attggaggta aaacaggaat taactatact 60 
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-continued 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 120 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtaaat 180 
gcaccatttg tttgtcaaaa taattgtcct ggtcaattat ttgtaaaagt tgcgcctaat 240 
ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt aacttactca 300 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc tcatacttgg 360 
aatccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt accaagtaat 420 
attggaggta tgaaaattgt a 441 
<210> SEQ ID NO 4 
<211> LENGTH, 441 
<212> TYPE, DNA 
<213> ORGANISM, Canine parvovirus 
<400> SEQUENCE, 4 
gaagataatg tattgctacc aacagatcca attggaggta aagcaggaat taactatact 60 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 120 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtaaat 180 
gcaccatttg tttgtcaaaa taattgtcct ggtcaattat ttgtaaaagt tgcgcctaat 240 
ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt aacttactca 300 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc tcatacttgg 360 
aatccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt accaagtaat 420 
attggaggta tgaaaattgt a 441 
<210> SEQ ID NO 5 
<211> LENGTH, 441 
<212> TYPE, DNA 
<213> ORGANISM, Canine parvovirus 
<400> SEQUENCE, 5 
gaagataatg tattactacc aacagatcca attggaggta aagcaggaat taactatact 60 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 120 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtaaat 180 
gcaccatttg tttgtcaaaa taattgtcct ggtcaattat ttgtaaaagt tgcgcctaat 240 
ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt aacttactca 300 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc tcatacttgg 360 
aatccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt accaagtaat 420 
attggaggta tgaaaattgt a 441 
<210> SEQ ID NO 6 
<211> LENGTH, 441 
<212> TYPE, DNA 
<213> ORGANISM, Canine parvovirus 
<400> SEQUENCE, 6 
gacgataatg tattgctacc aacagatcca attggaggta aaacaggaat taactatact 60 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 120 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtgaat 180 
gcaccatttg tttgtcaaaa taattgccct ggtcaattat ttgtaaaagt tgcgcctaat 240 
ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt aacttactca 300 
US 8,609,404 B2 
23 24 
-continued 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc tcatacttgg 360 
420 
441 
aacccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt accaagtaat 
attggaggta tgaaaattgt c 
We claim: 
1. A recombinant vector that contains and expresses a 
nucleic acid sequence encoding a canine parvovirus VP-2 
protein, wherein said nucleic acid sequence is at least 99% 
homologous to SEQ ID NO: 6, wherein: nucleotides 1-3 of 
said nucleic acid sequence are GAC to encode Asp at position 
426 of said VP-2 protein, nucleotides 175-177 of said nucleic 
acid sequence are GTG to encode Val at position 484 of said 
VP-2 protein, and nucleotides 361-363 of said nucleic acid 
sequence areAAC to encodeAsn at position 546 of said VP-2 
protein. 
2. The recombinant vector of claim 1, wherein said nucleic 
acid sequence encoding a canine parvovirus VP-2 protein is 
SEQ ID NO: 6. 
3. The recombinant vector of claim 1, wherein said recom-
binant vector further comprises one or more nucleic acid 
sequences encoding a VP-2 protein selected from the group 
consisting of: SEQ ID NO: 1; a portion of SEQ ID NO: 1 that 
encodes an antigenic region of said VP-2 protein; SEQ ID 
NO:2; a sequence that is at least 95% homologous to SEQ ID 
NO: 2, wherein nucleotides 16-18 are CTG to encode Leu at 
position 431 of said VP-2 protein; SEQ ID NO: 3; a portion of 
SEQ ID NO: 3 that encodes an antigenic region of said VP-2 
protein; SEQ ID NO: 4; a sequence that is at least 95% 
homologous to SEQ ID NO: 4 and wherein nucleotides 43-45 
are GCA to encode Ala at position 440 of said VP-2 protein; 
SEQ ID NO: 5, a portion of SEQ ID NO: 5 that encodes an 
antigenic region of said VP-2 protein; a nucleic acid sequence 
encoding a CP-V2 VP-2 protein, a nucleic acid sequence 
encoding a CP-V2a VP-2 protein, a nucleic acid sequence 
encoding a CP-V2b VP-2 protein, a nucleic acid sequence 
encoding a CP-V2c VP-2 protein. 
4. The recombinant vector of claim 3, wherein said recom-
binant vector is selected from the group consisting of bacte-
rial vectors, pro biotic-based expression vectors viral vectors 
and yeast expression vectors. ' ' 
5. The recombinant vector of claim 3, wherein said bacte-
rial vector is an Escherichia coli vector. 
6. The recombinant vector of claim 3, wherein said pro bi-
otic-based expression vector is a Lactobacillus vector. 
7. The recombinant vector of claim 3, wherein said viral 
vectors are adenoviral vectors or baculovirus vectors. 
8. The recombinant vector of claim 3, wherein said yeast 
expression vectors is a Pichia vector. 
9. An immunogenic composition comprising a recombi-
nant vector that contains and expresses a nucleic acid 
sequence encoding a canine parvovirus VP-2 protein, 
wherein said nucleic acid sequence is at least 99% homolo-
gous to SEQ ID NO: 6, wherein: nucleotides 1-3 of said 
nucleic acid sequence are GAC to encode Asp at position 426 
of saidVP-2 protein, nucleotides 175-177 of said nucleic acid 
sequence are GTG to encode Val at position 484 of said VP-2 
protein, and nucleotides 361-363 of said nucleic acid 
sequence areAAC to encodeAsn at position 546 of said VP-2 
protein. 
10 10. The immunogenic composition of claim 9, wherein 
said nucleic acid sequence encoding a canine parvovirus 
VP-2 protein is SEQ ID NO: 6. 
11. The immunogenic composition of claim 9 wherein 
said recombinant vector further comprises one' or more 
15 nucleic acid sequences selected from the group consisting of: 
SEQ ID NO: 1; a portion of SEQ ID NO: 1 that encodes an 
antigenic region of said VP-2 protein; SEQ ID NO:2; a 
sequence that is at least 95% homologous to SEQ ID NO: 2, 
wherein nucleotides 16-18 are CTG to encode Leu at position 
20 
431 ofsaidVP-2 protein; SEQ IDNO: 3; a portion of SEQ ID 
NO: 3 that encodes an antigenic region of said VP-2 protein; 
SEQ ID NO: 4; a sequence that is at least 95% homologous to 
SEQ ID NO: 4 and wherein nucleotides 43-45 are GCA to 
encode Ala at position 440 of said VP-2 protein; SEQ ID NO: 
5, a portion of SEQ ID NO: 5 that encodes an antigenic region 
25 of said VP-2 protein; a nucleic acid sequence encoding a 
CP-V2 VP-2 protein, a nucleic acid sequence encoding a 
CP-V2a VP-2 protein, a nucleic acid sequence encoding a 
CP-V2b VP-2 protein, a nucleic acid sequence encoding a 
CP-V2c VP-2 protein. 
30 12. The immunogenic composition of claim 9, wherein 
said immunogenic composition further comprises one or 
more recombinant vectors that contain and express one or 
more nucleic acid sequences selected from the group consist-
ing of: SEQ ID NO: 1; a portion of SEQ ID NO: 1 that encodes 
35 an antigenic region of said VP-2 protein; SEQ ID NO:2; a 
sequence that is at least 95% homologous to SEQ ID NO: 2, 
wherein nucleotides 16-18 are CTG to encode Leu at position 
431 ofsaidVP-2 protein; SEQ IDNO: 3; a portion of SEQ ID 
NO: 3 that encodes an antigenic region of said VP-2 protein; 
40 SEQ ID NO: 4; a sequence that is at least 95% homologous to 
SEQ ID NO: 4 and wherein nucleotides 43-45 are GCA to 
encode Ala at position 440 of said VP-2 protein; SEQ ID NO: 
5, a portion of SEQ ID NO: 5 that encodes an antigenic region 
of said VP-2 protein; a nucleic acid sequence encoding a 
45 CP-V2 VP-2 protein, a nucleic acid sequence encoding a 
CP-V2a VP-2 protein, a nucleic acid sequence encoding a 
CP-V2b VP-2 protein, a nucleic acid sequence encoding a 
CP-V2c VP-2 protein. 
13. The immunogenic composition of claim 9, wherein 
50 said recombinant vector is selected from the group consisting 
of bacterial vectors, probiotic-based expression vectors, 
adenoviral vectors, baculovirus vectors, and yeast expression 
vectors. 
14. The immunogenic composition of claim 13, wherein 
55 said bacterial vector is an Escherichia coli vector. 
15. The immunogenic composition of claim 13, wherein 
said pro biotic-based expression vector is aLactobacillus vec-
tor. 
16. The immunogenic composition of claim 13, wherein 
60 said viral vectors are adenoviral vectors or baculovirus vec-
tors. 
17. The immunogenic composition of claim 13, wherein 
said yeast expression vector is a Pichia vector. 
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